Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)

被引：0
|
作者：
Di Cosimo, S
Matar, P
Rojo, F
Guzman, M
Rodriguez, S
Jimenez, J
Arribas, J
Cognetti, F
Lane, H
Baselga, J
机构：
[1] Vall Hebron Univ Hosp, Barcelona, Spain
[2] Regina Elena Inst Canc Res, I-00161 Rome, Italy
[3] Novartis Pharma AG, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3074
引用
收藏
页码：213S / 213S
页数：1
相关论文
共 50 条
  • [21] Augmented growth inhibition of human NSCLC cells resistant to EGFR-tyrosine kinase inhibitor (TKI) by a combination of dual TKI of EGFR/VEGFR2 (AEE788) and mTOR inhibitor (RAD001)
    Soejima, K.
    Nakachi, I.
    Naoki, K.
    Watanabe, H.
    Kawada, I.
    Yasuda, H.
    Ishizaka, A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 183 - 183
  • [22] A phase I trial of a combination of the mTOR Inhibitor Everolimus (RAD001) and two schedules of the vascular enclothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK 222584) in patients (pts) with advanced solid tumors
    Dy, G.
    Croghan, G.
    Furth, A.
    Reid, J.
    Hanson, L.
    Roos, M.
    Tan, A.
    Adjei, A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 15 - 15
  • [23] Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib
    Govindan, R
    Behnken, D
    Read, W
    McLeod, H
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1330 - 1331
  • [24] Tailored therapeutic strategies for synovial sarcoma: Receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001
    Yasui, Hirohiko
    Naka, Norifumi
    Imura, Yoshinori
    Outani, Hidetatsu
    Kaneko, Keiko
    Hamada, Ken-ichiro
    Sasagawa, Satoru
    Araki, Nobuhito
    Ueda, Takafumi
    Itoh, Kazuyuki
    Myoui, Akira
    Yoshikawa, Hideki
    CANCER LETTERS, 2014, 347 (01) : 114 - 122
  • [25] Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
    Goudar, RK
    Shi, Q
    Hjelmeland, MD
    Keir, ST
    McLendon, RE
    Wikstrand, CJ
    Reese, ED
    Conrad, CA
    Traxler, P
    Lane, HA
    Reardon, DA
    Cavenee, WK
    Wang, XF
    Bigner, DD
    Friedman, HS
    Rich, JN
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (01) : 101 - 112
  • [26] Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Tobinai, Kensei
    Ogura, Michinori
    Maruyama, Dai
    Uchida, Toshiki
    Uike, Naokuni
    Choi, Ilseung
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Shimada, Naomi
    Kobayashi, Ken
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (04) : 563 - 570
  • [27] Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Kensei Tobinai
    Michinori Ogura
    Dai Maruyama
    Toshiki Uchida
    Naokuni Uike
    Ilseung Choi
    Kenichi Ishizawa
    Kuniaki Itoh
    Kiyoshi Ando
    Masafumi Taniwaki
    Naomi Shimada
    Ken Kobayashi
    International Journal of Hematology, 2010, 92 : 563 - 570
  • [28] Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors
    Giaccone, G
    González-Larriba, JL
    van Oosterom, AT
    Alfonso, R
    Smit, EF
    Martens, M
    Peters, GJ
    van der Vijgh, WJF
    Smith, R
    Averbuch, S
    Fandi, A
    ANNALS OF ONCOLOGY, 2004, 15 (05) : 831 - 838
  • [29] Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man
    McKillop, D
    Hutchison, M
    Partridge, EA
    Bushby, N
    Cooper, CMF
    Clarkson-Jones, JA
    Herron, W
    Swaisland, HC
    XENOBIOTICA, 2004, 34 (10) : 917 - 934
  • [30] The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan
    Braun, AH
    Stark, K
    Dirsch, O
    Hilger, RA
    Seeber, S
    Vanhoefer, U
    ANTI-CANCER DRUGS, 2005, 16 (10) : 1099 - 1108
12345